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showed a decreasing tendency following the introduction of
organized screening programme.
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OBJECTIVE: The cost of illness due to cancer is substantial in
terms of both human suffering and economic resources. The
growth in cancer treatment spending in the United States is due in
large part to increases in survival and cancer prevalence. The
objective of this study is to analyze the growth in spending on
direct medical costs for cancer treatment using a prevalence-based
cost-of-illness approach. Direct costs include personal health care
expenditures for hospital and nursing home care, physician and
other professional services, drugs, and home care. METHODS:
Estimates for cancer prevalence counts in the year 2004 were
derived by applying U.S. Census population data to National
Cancer Institute Surveillance Epidemiology and End Results
(SEER 9) and historical Connecticut Limited Duration Prevalence
proportions. Cancer treatment cost estimates were based on
Centers for Medicare & Medicaid Services projections for total
2005 health expenditures by type of direct costs, and the National
Center for Health Statistic’s methodology for calculating direct
costs for major diagnostic groups. Cancer treatment spending and
national health care expenditure values were adjusted to year
2005 dollars using the Consumer Price Index—All Urban Con-
sumers. RESULTS: From 1985 to 2004, inﬂation adjusted per-
capita national health care expenditures increased 70%, while
inﬂation adjusted cancer treatment spending per prevalent case
increased 16%. In 2004, cancer spending per prevalent case
($6862) was on par with per-capita total health care spending
($6492). CONCLUSION: Per-capita health care spending has
increased signiﬁcantly over the past two decades in comparison to
cancer spending per prevalent case. Prevalence-based costing
acknowledges that the direct costs of cancer care in any given year
are attributable to new and previously diagnosed cancer patients.
Our analysis underscores the importance of evaluating spending
on cancer care in the context of overall health care spending,
cancer survival rates, and disease prevalence.
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OBJECTIVE: Cancer continues to be a leading cause of death,
but the last few decades have seen many changes in the diagnosis
and treatment of the disease. In this study, we estimate the
economic value of gains in cancer survival over the last 20 years,
separate these gains into the portions due to improvements in
treatment and detection, and determine the extent to which the
economic value of gains in cancer survival have been divided
between patients and ﬁrms. METHODS: Using methodology
developed by Philipson and Jena (2005), we estimated the eco-
nomic value of gains in cancer survival between 1990 and 2000.
We then used estimates from the literature to calculate expendi-
tures on cancer treatment, thereby allowing us to determine how
the social value of gains in cancer treatment has been divided
between patients and ﬁrms. RESULTS: The value of survival
gains for all cancers combined was worth roughly $28,000–
$30,000 per cancer patient, and most (78–88%) of this gain has
been driven by improvements in treatment. For all cancers com-
bined, improvements in cancer survival between 1990 and 2000
had a social value of roughly $1.6–$1.9 trillion, and health care
providers were able to appropriate 6–19% of this total, with the
rest accruing to patients. CONCLUSION: The social value of
recent gains in cancer survival is very large. Most of this gain has
been driven by improvements in cancer treatment, and has been
appropriated by patients, not health care providers.
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OBJECTIVE: To describe how decision making in the Cancer
Subcommittee of the Ontario Committee to Evaluate Drugs
(responsible for deciding which novel and costly cancer drugs
will be funded in Ontario) is evolving along three scientiﬁc para-
digms. METHODS: We describe how these paradigms shape
both criteria and process of decision making. We also systemati-
cally reviewed meeting transcripts to analyze decisions made in
2006. RESULTS: Evidence Based Medicine (I) is part of decision
making through rigorous evidence reviews and the implicit rule
that drugs must pass the threshold of effectiveness to be funded.
Although drugs must pass one evidence threshold to be licenced
in Canada, higher standards are required for reimbursement (e.g.
phase III controlled trial data, peer reviewed publication). Health
economic criteria (II) are assuming greater weight in decision
making, as the review process is standardized, committee
members become more economically literate, and a cancer phar-
macoeconomics unit is established. The process of decision
making (versus decision criteria) is evolving using the ethical
foundations of Accountability for Reasonableness (III), impor-
tant tenets of which are transparency, accountability, and stake-
holder involvement in the decision process. Review of the 2006
decisions showed that 16 of 37 drugs were funded (43%).
Among negative funding decisions 86% were characterized by
inadequate evidence (main reason in 43%), 71% were charac-
terized by cost effectiveness concerns (main reason in 15% ), and
5% by ethical concerns (main reason in 5%). Forty-eight percent
of decisions were multifactorial. CONCLUSION: Each para-
digm used to make cancer drug funding decisions comes from a
distinct intellectual tradition. Most decisions in 2006 were based
on more than one paradigm. We believe that optimal decision
making for cancer drugs involves integrating concepts from all
traditions, involving both distinct decision criteria and decision
processes. Integration requires judicious tradeoffs between both
efﬁciency and equity, and evidence quality and efﬁciency/equity.
PCN94
PREDICTORS OFTREATMENT CHOICE IN HIGH RISK AND
METASTATIC MELANOMA: EVIDENCE FROM LINKED
ELECTRONIC MEDICAL RECORDS AND ADMINISTRATIVE
CLAIMS DATA
Kotapati S1, Mitra D2, Davis KL2, Iloeje U3
1Bristol-Myers Squibb Co,Wallingford, CT, USA, 2RTI Health Solutions,
Research Triangle Park, NC, USA, 3Bristol-Myers Squibb,Wallingford,
CT, USA
OBJECTIVE: Evaluate predictors of four major therapeutic
choices (surgery, radiation, chemotherapy, immunotherapy) in
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high-risk (stage IIB/C, III) and metastatic (stage IV) melanoma.
METHODS: Data were acquired from Convergence CT, a
company that links longitudinal electronic medical records and
claims data from large physician practices, clinics, ambulatory
centers, and hospitals in the US. Subjects with 1 diagnosis of
malignant melanoma (ICD-9 172.xx, 173.xx, V10.82) from July
1, 2003 November 30, 2006 and pathology-conﬁrmed disease
stage of IIB/C, III, or IV were selected. Additional stage IV
patients were identiﬁed based on evidence of a subsequent ICD-9
code (197.xx, 198.xx) for secondary metastases. Post-diagnosis
prevalence of the key treatments was analyzed descriptively.
Logistic regression was used to assess predictors of therapeutic
choice. RESULTS: A total of 268 subjects were identiﬁed. Stage
distribution was: IIB/C (18%); III (21%); IV (61%). 58% were
65 years of age and 62% were male. Surgery was the predomi-
nant treatment in stage IIB/C and III (received by >80% of
subjects), but was seen in only 38% of stage IV patients. Across
all stages, radiation, chemotherapy, and immunotherapy were
less common (23%, 27%, and 10%, respectively). Being elderly
[odds ratio = 2.19; 95% CI = (1.10–4.35)] and having stage IV
disease [7.31 (2.38–22.39)] was associated with a signiﬁcantly
increased likelihood of receiving no active treatment. Older age
(65+), higher co-comorbidity burden, and having stage IV disease
were associated with a decreased probability of surgery [0.55
(0.30–0.99), 0.92 (0.86–0.99), 0.08 (0.03–0.22), respectively].
Receiving radiation was reduced by older age, but increased by
having stage IV disease [2.38 (0.91–6.22)]. Signiﬁcant predictors
of chemotherapy were stage IV disease [2.65 (1.01–6.93)] and
higher co-morbidity burden [1.08 (1.01–1.17)]. Finally,
increasing age substantially reduced the likelihood of receiving
immunotherapy [0.24 (0.10–0.60)]. CONCLUSION: Factors
inﬂuencing practice patterns and treatment choice in a popula-
tion with high risk or metastatic melanoma. Across therapeutic
choices, age and disease stage were the signiﬁcant predictors.
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OBJECTIVE: Using 12 years of administrative data, we assessed
the trends in the use of breast conserving surgery (BCS) before
and after the release of clinical guidelines on BCS in Japan
(published in 1999 and updated in 2005.) METHODS: We used
a database from the Quality Improvement/Indicator Project that
involved 40 teaching hospitals in Japan. Data on all discharged
cases were collected from these hospitals from 1995. We then
selected female operable breast cancer patients who were
admitted to ﬁve of these hospitals from January 1996 through
September 2007 (n = 1971). A multiple regression analysis was
performed to examine whether the proportion of the use of BCS
after publication of guidelines was higher than that before pub-
lication, after adjusted for the effects of patient’s age, comorbid-
ity status (Charlson Comorbidity Index), hospital, and time
period of admission. The Hosmer-Lemeshow test was conducted
to assess the goodness-of-ﬁt of the model. RESULTS: The pro-
portion of BCS use increased from 16.1% in 1996 to 62.2% in
2007. Multiple logistic regression analysis revealed that patients
who were <50 years old (P < 0.001) and had no comorbidity
(P < 0.001) were signiﬁcantly more likely to receive BCS. The
proportion of BCS use has been substantially higher since 2001,
two years after the BCS guidelines were published in Japan.
Signiﬁcant practice variations of BCS use were also conﬁrmed
among hospitals. CONCLUSION: This study conﬁrmed the lag
time between guideline publication and change in practice of BCS
use. We further need to examine the potential barriers to guide-
line adoption related to physicians’ knowledge and attitudes as
well as external barriers including patient-, guideline-, and
environment-related factors, to explain the reasons of change in
the use of BCS over ten years.
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OBJECTIVE: To document real-world treatment patterns in
elderly patients with high-risk (stage IIB/C, IIIA/B, IIIC) or meta-
static (stage IV) melanoma. METHODS: Data was taken from
the Surveillance, Epidemiology, and End Results (SEER)-
Medicare linked database combining clinical information on
incident cancer cases in the US between 1991 and 2002 with
longitudinal (1991–2005) Medicare claims. Subjects 65 years
with 1 stage IIB or higher melanoma diagnosis and 6 months
of subsequent beneﬁts coverage were selected. We documented
utilization patterns of four major therapies (surgery, radiation,
chemotherapy, immunotherapy) following the diagnosis.
RESULTS: A total of 6470 subjects met all criteria. Stage distri-
bution was: IIB/C (38%); IIIA/B (46%); IIIC (1%); IV (15%).
Median follow-up was 56, 39, 16, and 6 months, respectively.
Surgery (primarily tumor excision) was the predominant 1st line
treatment, received by >85% of subjects with stage IIB/C, IIIA/B,
or IIIC melanoma and 60% of stage IV cases, but was a rare 2nd
line approach. Radiation was 1st line treatment in only 2%, 5%,
and 13% of stage IIB/C, IIIA/B, and IIIC cases, respectively,
but was more common as a 2nd line approach in these subjects
(15%, 24%, and 41%, respectively). Radiation was equally
prevalent (~30% of cases) as 1st or 2nd line treatment in stage IV.
Chemotherapy was uncommon as 1st line treatment (<4% of all
cases), but prevalent as 2nd line therapy (by respective stage,
14%, 20%, 41%, and 22% of cases). Immunotherapy was rare,
except as 2nd line treatment in stage IIIC (26% of cases). CON-
CLUSION: Beyond surgery as a 1st line approach, relatively few
patients received other types of treatment as either 1st or 2nd line
therapy. These ﬁndings demonstrate an unmet need in high risk
and metastatic melanoma. Additional analyses of administrative
data characterizing real-world treatment patterns in melanoma
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OBJECTIVE: Numerous randomized controlled trials (RCTs)
have evaluated efﬁcacy of proton-pump inhibitors (PPIs) in con-
trolling nighttime symptoms of gastroesophageal reﬂux disease
(GERD). Quantitative synthesis of the effect of PPIs on nighttime
symptoms is lacking, thus the validity of performing a meta-
analysis was assessed. METHODS: MEDLINE and EMBASE
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